Oruka Therapeutics Inc. (ORKA)
NASDAQ: ORKA
· Real-Time Price · USD
10.64
0.55 (5.45%)
At close: May 02, 2025, 12:31 PM
5.45% (1D)
| Bid | 7.52 |
| Market Cap | 398.55M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | n/a |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 13.19 |
| Volume | 37,124 |
| Avg. Volume (20D) | 284,638 |
| Open | 10.11 |
| Previous Close | 10.09 |
| Day's Range | 10.07 - 10.72 |
| 52-Week Range | 5.49 - 53.88 |
| Beta | 0.19 |
About ORKA
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA....
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 28
Stock Exchange NASDAQ
Ticker Symbol ORKA
Website http://www.orukatx.com
Analyst Forecast
According to 8 analyst ratings, the average rating for ORKA stock is "Buy." The 12-month stock price forecast is $44, which is an increase of 313.34% from the latest price.
Stock Forecasts5 months ago
-6.43%
Oruka Therapeutics shares are trading lower after ...
Unlock content with
Pro Subscription
7 months ago
+9.76%
Oruka Therapeutics shares are trading higher after Wedbush initiated coverage on the stock with an Outperform rating and announced a $40 price target.